Ligand to Report Second Quarter Financial Results on July 29, 2021
July 16 2021 - 9:00AM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will
report financial results for the three and six months ended June
30, 2021 after the close of the U.S. financial markets on Thursday,
July 29, 2021 and will hold a conference call that same day
beginning at 4:30 p.m. Eastern time. Speakers on the call will
include Ligand’s CEO John Higgins, President and COO Matt Foehr and
Executive Vice President and CFO Matt Korenberg.
Conference Call and Webcast Information
What:
Ligand conference call to discuss second
quarter 2021 financial results and provide general business
updates
Date:
Thursday, July 29, 2021
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific
time)
Conference Call:
Dial (833) 540-1167 within the U.S.
Dial (929) 517-0358 outside the U.S.
Conference ID is 5089624
Webcast:
Live and replay webcast of the call are
available here.
About Ligand Pharmaceuticals
Ligand is a revenue-generating biopharmaceutical company focused
on developing or acquiring technologies that help pharmaceutical
companies discover and develop medicines. Ligand’s business model
creates value for stockholders by providing a diversified portfolio
of biotech and pharmaceutical product revenue streams that are
supported by an efficient and low corporate cost structure.
Ligand’s goal is to offer investors an opportunity to participate
in the promise of the biotech industry in a profitable, diversified
and lower-risk business than a typical biotech company. Ligand’s
business model is based on doing what Ligand does best: drug
discovery, early-stage drug development, product reformulation and
partnering. Ligand partners with other pharmaceutical companies to
leverage what they do best (late-stage development, regulatory
affairs and commercialization) to ultimately generate our revenue.
Ligand’s OmniAb® technology platform is a patent-protected
technology stack used in the discovery of fully human mono- and
bispecific therapeutic antibodies. The Captisol® platform
technology is a patent-protected, chemically modified cyclodextrin
with a structure designed to optimize the solubility and stability
of drugs. Ligand’s Pelican Expression Technology™ is a robust,
validated, cost-effective and scalable approach to recombinant
protein production, and is especially well-suited for complex,
large-scale protein production that cannot be made by traditional
systems. Ligand has established multiple alliances, licenses and
other business relationships with the world’s leading
pharmaceutical companies including Amgen, Merck, Pfizer, Roche,
Jazz Pharmaceuticals, Sanofi, Janssen, Takeda, Gilead Sciences, GSK
and Baxter International. For more information, please visit
www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210716005056/en/
Ligand Pharmaceuticals Incorporated Simon Latimer
investors@ligand.com (858) 550-7766 Twitter: @Ligand_LGND
LHA Investor Relations Bruce Voss bvoss@lhai.com
(310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Jul 2023 to Jul 2024